Ruxolitinib + Enasidenib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Accelerated/Blast-phase Myeloproliferative Neoplasm

Conditions

Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation

Trial Timeline

Jan 14, 2021 → May 30, 2023

NCT ID

NCT04281498

About Ruxolitinib + Enasidenib

Ruxolitinib + Enasidenib is a phase 2 stage product being developed by Incyte for Accelerated/Blast-phase Myeloproliferative Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT04281498. Target conditions include Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04281498	Phase 2	Completed	Jan 14, 2021	May 30, 2023	Accelerated/Blast-phase Myeloproliferative Neoplasm